Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05194072 · ClinicalTrials.gov registry record · Phase 1
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
A Phase 1 study, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
NCT05194072 is a Phase 1 study that was terminated before completion, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 250 participants.
The verdict
NCT05194072, a Phase 1 study, was terminated before completion, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine. A side effect is anything a medicine does to the body besides treating the disease. This study is seeking for participants who either have cancer: * that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable), * has spread through the body (metastatic), or have some cancer left over after surgery. This study will have five parts. * Parts A and B of the study will find out how much Felmetatug Vedotin should be given to participants. * Part C will use the amount found in Parts A and B to find out how safe Felmetatug Vedotin is and if it works to treat solid tumor cancers. * Part D will find out if and how much Felmetatug Vedotin can be given with pembrolizumab. * Part E will use the amount found in Part D to find out how safe Felmetatug Vedotin with pembrolizumab is and if it works to treat triple negative breast cancer.
Interventions
- DRUG Pembrolizumab
- DRUG Felmetatug Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2022-01-12 |
| Est. Completion | 2025-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05194072
The ClinicalTrials.gov registry entry for NCT05194072 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05194072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05194072 about?
NCT05194072 is a clinical study titled "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors". The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine. A side effect is anything a medicine does to the body besides treating the disease. This s...
What is the current status of trial NCT05194072?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2022-01-12. Estimated completion is 2025-05-14.
What interventions are being tested in trial NCT05194072?
The interventions under investigation include: Pembrolizumab (DRUG), Felmetatug Vedotin (DRUG).
Who is sponsoring clinical trial NCT05194072?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.